{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-022337","form_type":"8-K","ticker":null,"cik":"0000799698","company_name":"LadRx Corp","filed_at":"2023-06-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.266172+00:00","generated_at":"2026-06-13T17:24:56.866712+00:00","sec_items":["1.01","2.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"LadRx sells aldoxorubicin and arimoclomol royalty rights to XOMA for $5M upfront; up to $6M more","bullets":["Gross proceeds $5M at closing; potential $6M milestones: $1M on FDA acceptance of arimoclomol NDA, $1M on first sale, $4M on aldoxorubicin FDA approval.","XOMA acquires all milestone and royalty payments from ImmunityBio and Zevra, net of existing obligations.","Proceeds to advance lead candidate LADR-7 toward IND filing; 12 months of final IND-enabling work estimated.","Transaction structured as non-dilutive financing; Roth Capital Partners acted as placement agent."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-022337","json":"https://secwatch.observer/filing/0001493152-23-022337.json","markdown":"https://secwatch.observer/filing/0001493152-23-022337.md","text":"https://secwatch.observer/filing/0001493152-23-022337.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/799698/000149315223022337/0001493152-23-022337-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/799698/000149315223022337/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T17:24:56.866712+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2233db301cb054baffcff335b0f51c5b3bac9966","claim":"LadRx Corp completed a disposition involving XOMA (US) LLC for $5 million (closed 2023-06-21).","evidence_excerpt":"purchase price paid to the Company for the sale, transfer, assignment and conveyance of the Company’s right, title and interest in and to aldoxorubicin and arimoclomol was $5 million, less certain transaction fees and expenses. As previously reported, on July 27, 2017, the Company entered into an exclusive worldwide license agreement (as amended, the “","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/799698/000149315223022337/0001493152-23-022337-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"XOMA (US) LLC"},{"label":"Consideration","value":"$5 million"},{"label":"Closing","value":"2023-06-21"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}